Ingram, John R. http://orcid.org/0000-0002-5257-1142
Geissbühler, Yvonne http://orcid.org/0000-0001-8528-6818
Darcy, John II
Foley, Stephen
Gaffney, Alex
McConnon, Aine
Richardson, Craig
Garg, Amit
Funding for this research was provided by:
Novartis
Article History
Received: 6 June 2024
Accepted: 13 August 2024
First Online: 24 September 2024
Declarations
:
: John R. Ingram is a consultant for Abbvie, Boehringer Ingelheim, ChemoCentryx, Citryll, MoonLake, Novartis, UCB Pharma, and UNION Pharmaceuticals and has served on advisory boards for Insmed, Kymera Therapeutics and Viela Bio. Until recently, he was BJD Editor-in-Chief and receives an authorship honorarium for two UpToDate HS chapters. He is co-copyright holder of HiSQOL and Investigator and Patient Global Assessment instruments for HS. His department receives income from copyright of the Dermatology Life Quality Instrument (DLQI) and related instruments. Yvonne Geissbühler, John Darcy II, and Aine McConnon are employees and/or shareholders of Novartis. Craig Richardson, Stephen Foley, and Alex Gaffney were employees of Novartis at the time of the study. Amit Garg is an advisor for AbbVie, Boehringer Ingelheim, Incyte, Insmed, Novartis, Pfizer, Sonoma Biotherapeutics, Sun Pharma, UCB, Union Therapeutics, and Zura Bio, and receives honoraria.
: All data included in this manuscript were obtained from claims and electronic health record databases; no patient-level data were collected or stored.